Organon & Co. (NYSE:OGN) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Organon & Co. (NYSE:OGN) released its quarterly earnings results on Thursday. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09), Zacks reports. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co. updated its FY 2025 guidance to EPS.

Organon & Co. Stock Performance

Organon & Co. stock traded down $1.03 during trading on Friday, reaching $15.30. The company had a trading volume of 4,424,393 shares, compared to its average volume of 2,305,809. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The firm’s 50-day simple moving average is $15.35 and its 200 day simple moving average is $17.48. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of 3.03, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be issued a $0.28 dividend. The ex-dividend date of this dividend is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.32%. Organon & Co.’s dividend payout ratio is currently 22.22%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Morgan Stanley decreased their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, Barclays decreased their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.